OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results
OPKO HEALTH, INC. (OPK) filed an SEC Form 8-K — Results of Operations and Financial Condition. OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results Conference Call to Begin Today at 4:30 p.m. ET MIAMI, November 4, 2026 – OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical company, today reports business highlights and financial re
How this was made
The 30-second read
Why it matters
The disclosed cash consideration and royalty revenue boost provide a clear catalyst for short‑term price movement.
Market read
First‑report primary disclosure of a multi‑hundred‑million‑dollar transaction and earnings, offering actionable trading insight.
What to watch
Regulatory approvals for the sale could delay cash receipt, and integration risks for Labcorp may affect long-term value.
OPKO Health reported third-quarter continuing-operations revenue of $65.4 million, up 16%, while its continuing-operations net loss widened to $35.5 million; the company agreed to sell substantially all remaining BioReference diagnostic operations to Labcorp.
Continuing-operations revenue increased to $65.4 million and Global Products returned to segment operating income, but Innovative Biotech losses widened, continuing-operations net loss increased, discontinued operations recorded an $18.0 million loss, and services-revenue guidance was withdrawn pending the Labcorp transaction.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenues, three months ended September 30, 2026GAAP | $65.4M | – | 16% |
| Revenue from products, three months ended September 30, 2026GAAP | $41.8M | – | – |
| Licensing, collaboration and other revenue, three months ended September 30, 2026GAAP | $23.6M | – | – |
| International Operations revenue, three months ended September 30, 2026GAAP | $33.2M | – | – |
| Rayaldee revenue, three months ended September 30, 2026GAAP | $8.6M | – | – |
| NGENLA royalty and profit sharing, and cost sharing, three months ended September 30, 2026GAAP | $8.7M | – | – |
| BARDA revenue, three months ended September 30, 2026GAAP | $7.5M | – | – |
| Regeneron revenue, three months ended September 30, 2026GAAP | $800K | – | – |
| Other royalties and milestones, three months ended September 30, 2026GAAP | $6.6M | – | – |
| Cost of revenue, three months ended September 30, 2026GAAP | $23.3M | – | – |
| Selling, general and administrative expense, three months ended September 30, 2026GAAP | $24.8M | – | – |
| Research and development expense, three months ended September 30, 2026GAAP | $32.2M | – | – |
| Amortization of intangible assets, three months ended September 30, 2026GAAP | $16.5M | – | – |
| Total costs and expenses, three months ended September 30, 2026GAAP | $96.8M | – | – |
| Operating loss, three months ended September 30, 2026GAAP | −$31.4M | – | – |
| Non-cash depreciation, amortization and equity based compensation expense included in operating income (loss), three months ended September 30, 2026other | $20.7M | – | – |
| Other expense, net, three months ended September 30, 2026GAAP | −$6.4M | – | – |
| Loss before income taxes and investment losses, three months ended September 30, 2026GAAP | −$37.8M | – | – |
| Income tax benefit, three months ended September 30, 2026GAAP | $7.3M | – | – |
| Loss from investments in investees, three months ended September 30, 2026GAAP | −$5M | – | – |
| Net loss from continuing operations, three months ended September 30, 2026GAAP | −$35.5M | – | – |
| Loss per share from continuing operations, basic and diluted, three months ended September 30, 2026GAAP | $(0.05) | – | – |
| Revenue from discontinued operations, three months ended September 30, 2026GAAP | $71.8M | – | – |
| Operating loss from discontinued operations, three months ended September 30, 2026GAAP | −$18.8M | – | – |
| Income (loss) before income taxes from discontinued operations, three months ended September 30, 2026GAAP | −$18.7M | – | – |
| Income (loss) from discontinued operations, net of tax, three months ended September 30, 2026GAAP | −$18M | – | – |
| Income (loss) per share from discontinued operations, basic and diluted, three months ended September 30, 2026GAAP | $(0.02) | – | – |
| Net income (loss), three months ended September 30, 2026GAAP | −$53.5M | – | – |
| Net income (loss) per share, basic and diluted, three months ended September 30, 2026GAAP | $(0.07) | – | – |
| Total revenues, nine months ended September 30, 2026GAAP | $206.5M | – | – |
| Revenue from products, nine months ended September 30, 2026GAAP | $122.8M | – | – |
| Licensing, collaboration and other revenue, nine months ended September 30, 2026GAAP | $83.7M | – | – |
| Operating loss, nine months ended September 30, 2026GAAP | −$81.4M | – | – |
| Net loss from continuing operations, nine months ended September 30, 2026GAAP | −$91.2M | – | – |
| Net income (loss), nine months ended September 30, 2026GAAP | −$116.8M | – | – |
| Net income (loss) per share, basic and diluted, nine months ended September 30, 2026GAAP | $(0.16) | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Global Products, three months ended September 30, 2026Revenue from products was $41.8 million compared with $37.7 million, with Rayaldee revenue of $8.6 million driven by favorable gross-to-net adjustments from changes to Medicare Coverage; international operations increased approximately $3.0 million, including an approximately $0.7 million favorable foreign currency impact. Licensing, collaboration and other revenue was $6.6 million, primarily driven by $5.8 million of royalty revenue from Lilly. | $48.4M | – | – |
| Innovative Biotech, three months ended September 30, 2026Lower BARDA revenue of $7.5 million compared with $8.2 million was substantially offset by $0.8 million of collaboration revenue under the Regeneron agreement, while Pfizer royalty revenue was relatively consistent. | $17M | – | – |
For the three months ended December 31, 2026 and for the year ended December 31, 2026 outlook
- RevenueTotal revenue of $62.0 million to $72.0 million for the three months ended December 31, 2026; total revenue of $268.0 million to $278.0 million for the year ended December 31, 2026
- Operating expensesTotal costs and expenses from continuing operations of $100.0 million to $105.0 million for the three months ended December 31, 2026; $390.0 million to $395.0 million for the year ended December 31, 2026
- NoteServices revenue: Withdrawn
- NoteProduct revenue: $41.0 million to $46.0 million for the three months ended December 31, 2026; $164.0 million to $169.0 million for the year ended December 31, 2026
- NoteIP and other revenue: $21.0 million to $27.0 million for the three months ended December 31, 2026; $105.0 million to $110.0 million for the year ended December 31, 2026
- NotePfizer gross profit share included in revenue: $12.5 million to $15.0 million for the three months ended December 31, 2026; $34.0 million to $37.0 million for the year ended December 31, 2026
- NoteBARDA included in revenue: $3.0 million to $5.0 million for the three months ended December 31, 2026; $20.0 million to $22.0 million for the year ended December 31, 2026
- NoteR&D included in costs and expenses: $32.0 million to $35.0 million for the three months ended December 31, 2026; $125.0 million to $130.0 million for the year ended December 31, 2026
- NoteIncome/(loss) from discontinued operations: $(35.0) million to $(45.0) million for the three months ended December 31, 2026; $(60.0) million to $(70.0) million for the year ended December 31, 2026
Capital returns
- OPKO repurchased 7,050,000 shares during the quarter for approximately $10.6 million.
- As of September 30, 2026, approximately $115.7 million had been deployed under the $200 million share repurchase authorization, leaving approximately $84.3 million available.
What drove it
- Higher royalty revenue from Lilly, increased Rayaldee sales and growth in international operations principally drove the 16% increase in continuing-operations revenue.
- Rayaldee revenue benefited from favorable gross-to-net adjustments resulting from changes to Medicare Coverage.
- International operations reflected stronger performance in certain international markets, including animal health, higher EirGen sales volumes and favorable product mix.
- Innovative Biotech research and development expense increased primarily due to increased investment in ModeX development programs.
- The prior-year discontinued-operations result included a $101.6 million gain on the sale of BioReference's oncology diagnostics business and related clinical testing services assets to Labcorp.
Concerns
- Net loss from continuing operations was $(35.5) million compared with $(33.0) million in the prior-year quarter.
- Innovative Biotech segment operating loss was $(26.8) million compared with $(22.5) million in the prior-year quarter, while research and development expense was $30.4 million compared with $26.3 million.
- BioReference discontinued-operations revenue was $71.8 million compared with $95.2 million, and discontinued operations reported a loss of $(18.0) million compared with income of $54.6 million.
- OPKO withdrew previously issued guidance for services revenue due to uncertainty regarding the timing of the potential Labcorp closing and its impact on financial results.
- The Labcorp transaction remains subject to regulatory approvals and customary closing conditions.
What to watch
- Regulatory approvals and closing conditions for the Labcorp sale, which provides for $722 million in cash consideration at closing, subject to adjustments based on business revenues at closing, and up to $150 million in additional cash consideration over up to ten years based on Labcorp sales of the 4Kscore® test.
- Initial safety, tolerability, pharmacokinetic and immune data from MDX2001 and MDX2004, expected in the first half of 2027.
- Early MDX2301 data, expected in late 2026 or early 2027.
- Enrollment progress in the Phase 1/2a study of OPK-88006 and the Phase 1/2a trial of OPK-8801001.
- Execution against fourth-quarter and full-year continuing-operations revenue, cost and R&D guidance.
Balance sheet and cash flow
- Cash, cash equivalents and restricted cash were $403.2 million as of September 30, 2026.
- Cash, cash equivalents and current restricted cash were $390.2 million as of September 30, 2026, compared with $369.1 million as of December 31, 2025.
- During the quarter, OPKO received approximately $123.1 million of net proceeds from the additional royalty financing.
- During the quarter, OPKO received approximately $19.8 million from the release of escrow funds related to the September 2025 oncology transaction.
- Long-term portion of convertible notes was $92.5 million as of September 30, 2026, compared with $85.0 million as of December 31, 2025.
- Senior secured royalty financing was $370.2 million as of September 30, 2026, compared with $246.4 million as of December 31, 2025.
- Total liabilities were $764.1 million as of September 30, 2026, compared with $663.9 million as of December 31, 2025.
- Total shareholders' equity was $1,116.2 million as of September 30, 2026, compared with $1,268.0 million as of December 31, 2025.
Analysis
OPKO's continuing operations generated $65.4 million of third-quarter revenue, compared with $56.4 million in the prior-year quarter. The company attributed the increase principally to higher Lilly royalty revenue, Rayaldee sales and international operations. Product revenue was $41.8 million and licensing, collaboration and other revenue was $23.6 million, while the nine-month revenue base reached $206.5 million compared with $159.2 million.
Global Products was the principal improvement area. Segment revenue was $48.4 million compared with $39.4 million, and segment operating income was $6.0 million compared with an operating loss of $(1.2) million. Rayaldee revenue was $8.6 million, with the company citing favorable gross-to-net adjustments associated with Medicare Coverage. International operations revenue was $33.2 million, supported by animal health, EirGen volumes and product mix, as well as an approximately $0.7 million favorable foreign currency impact.
Innovative Biotech remained the principal operating-loss burden. Revenue was unchanged at $17.0 million, but segment operating loss increased to $(26.8) million from $(22.5) million as research and development expense rose to $30.4 million from $26.3 million. The company said lower BARDA revenue was substantially offset by Regeneron collaboration revenue, while increased ModeX development investment drove the expense increase. Consolidated operating loss narrowed to $(31.4) million from $(33.6) million, but net loss from continuing operations increased to $(35.5) million from $(33.0) million, including $5.0 million of loss from investments in investees.
The BioReference disposal changes the reporting perimeter. The business is now classified as discontinued operations following the September 30, 2026 approval of the Labcorp sale plan. BioReference revenue was $71.8 million compared with $95.2 million, and discontinued operations produced a loss of $(18.0) million versus income of $54.6 million in the prior-year quarter, which included a $101.6 million gain from the oncology diagnostics asset sale. The proposed remaining-business sale provides for $722 million in cash consideration at closing, subject to business-revenue adjustments, plus potential additional consideration tied to 4Kscore® sales.
Liquidity included $403.2 million of cash, cash equivalents and restricted cash, supplemented during the quarter by approximately $123.1 million of net royalty-financing proceeds and approximately $19.8 million of released escrow funds. OPKO repurchased 7,050,000 shares for approximately $10.6 million. For the fourth quarter, the company guided total continuing-operations revenue to $62.0 million to $72.0 million and total costs and expenses to $100.0 million to $105.0 million, while withdrawing services-revenue guidance because of uncertainty around the Labcorp transaction timing.
Not in the filing
stated, not guessed- Gross margin was not reported.
- Non-GAAP earnings, non-GAAP EPS and non-GAAP margin measures were not reported.
- Operating cash flow was not reported.
- Free cash flow was not reported.
- Dividend information was not reported.
- No prior outlook section with prior guidance figures was provided for comparison.
- No named executive quotes were included in the filing text.
- Guidance tax rate was not reported.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was checked against the filing text, and a metric whose value, prior period and change do not add up is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
OPKO Health, a Nasdaq-listed biopharma, filed an 8‑K reporting its Q3 2026 results and a major asset sale.
Ticker impact
OPKO Health disclosed a $722M cash sale of its BioReference diagnostic operations to Labcorp and reported Q3 2026 financial results.
upward pressure as investors price in the cash consideration and higher royalty income
Large cash transaction and better-than-expected revenue growth provide material upside catalysts.
Market effects
Potential consolidation in the diagnostic testing market as Labcorp expands its portfolio.
U.S. biotech sector may see modest gains from the transaction.
Limited to U.S. and international biotech investors.
Counterpoint
The divestiture could signal strategic weakness, and the loss of diagnostic revenue may pressure the stock.
Key entities
- companyOPKO Health
NASDAQ: OPK, biopharmaceutical company.
- companyLabcorp
Acquirer of OPKO's BioReference diagnostic operations.
